SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-131707"
 

Search: onr:"swepub:oai:DiVA.org:liu-131707" > Levodopa-carbidopa ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Pålhagen, Sven E.Karolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (author)

Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • ELSEVIER SCI LTD,2016
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-131707
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-131707URI
  • https://doi.org/10.1016/j.parkreldis.2016.06.002DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:134148541URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300787URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|AbbVie Inc.
  • Background: Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) can effectively manage motor and non-motor complications in advanced Parkinsons disease (PD). Healthcare costs, quality of life (QoL), effectiveness, and tolerability were assessed in routine care treatment with LCIG. Methods: The seventy-seven patients enrolled in this prospective, open-label, 3-year study in routine medical care were LCIG-naive (N = 37), or had previous LCIG treatment for amp;lt;2 (N = 22), or amp;gt;= 2 (N = 18) years. Healthcare costs were collected monthly. PD symptoms and QoL were assessed with the Unified Parkinsons Disease Rating Scale (UPDRS), 39-item Parkinsons Disease Questionnaire (PDQ-39), and EuroQoL 5-Dimension Visual Analog Scale (EQ-5D VAS); LCIG dose, safety, and tolerability were monitored. Results: Mean monthly costs per patient ( 8226 5952) were similar across cohorts, remained steady during 3-year follow-up, and increased with PD severity and QoL impairment. In LCIG-naive patients, significant improvements compared to baseline were observed on the UPDRS total score and PDQ-39 summary index score through 18 months (n = 24; UPDRS, p = 0.033; PDQ-39, p = 0.049). Symptom control was maintained during 3-year follow-up in LCIG-experienced cohorts. Small changes in mean daily LCIG dose were observed. Adverse events were common and generally related to the device, procedure, levodopa, or laboratory evaluations. Conclusions: Costs in LCIG-treated patients were stable over 3 years. LCIG treatment led to significant improvements in motor function and QoL over 18 months in LCIG-naive patients and no worsening was observed in LCIG-experienced patients over 3 years despite natural PD progression over time. The longterm safety was consistent with the established LCIG profile. (C) 2016 AbbVie Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sydow, OlofKarolinska University Hospital, Sweden,Karolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (author)
  • Johansson, AndersUppsala universitet,Karolinska Institutet,Neurologi(Swepub:uu)andejoha (author)
  • Nyholm, DagUppsala universitet,Neurologi(Swepub:uu)danyh856 (author)
  • Holmberg, BjornSahlgrens University Hospital, Sweden,Sahlgrens Univ Hosp, Dept Clin Neurosci, Gothenburg, Sweden (author)
  • Widner, HakanSkåne University Hospital, Sweden,Skane Univ Hosp, Dept Neurol, Lund, Sweden (author)
  • Dizdar Segrell, NilLinköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Linkoping Univ, Dept Neurol, Linkoping, Sweden; Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden(Swepub:liu)nildi39 (author)
  • Linder, JanNorrlands University Hospital, Sweden,Norrlands Univ Hosp, Neuroctr, Dept Neurol, Umea, Sweden (author)
  • Hauge, ToveMolde Hospital HNR, Norway,Molde Hosp HNR, Dept Neurol, Molde, Norway (author)
  • Jansson, RasmusSundsvall Hospital, Sweden,Sundsvall Hosp, Dept Geriatr Med & Rehabil, Sundsvall, Sweden (author)
  • Bergmann, LarsAbbVie Inc, N Chicago, IL USA (author)
  • Kjellander, SusannaAbbVie AB, Solna, Sweden (author)
  • Marshall, Thomas S.AbbVie Inc, N Chicago, IL USA (author)
  • Karolinska University Hospital, SwedenKarolinska Univ Hosp, Dept Neurol, SE-14186 Stockholm, Sweden (creator_code:org_t)

Related titles

  • In:Parkinsonism & Related Disorders: ELSEVIER SCI LTD29, s. 17-231353-80201873-5126

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view